small molecule

DIFICID

FIDAXOMICIN

Loss of exclusivityNovember 2034latest FDA-listed patent expiry

CompanyCubist Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	DIFICID
Active ingredient	FIDAXOMICIN
Strength	40MG/ML
Dosage form	FOR SUSPENSION
Route	ORAL
Modality	Small molecule
FDA approval	January 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
9808530*PED	November 2034	—
9808530	May 2034	product
8859510*PED	January 2028	—
7378508*PED	January 2028	—
7863249*PED	January 2028	—
7906489*PED	September 2027	—
8859510	July 2027	use U-2741
7863249	July 2027	product
7378508	July 2027	substance, product
7906489	March 2027	use U-2741

Regulatory exclusivity

Code	Expires
ODE-367	January 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Cubist Pharmaceuticals